Skip to content

Mobile Advanced Multi-Parameter Reporting in Patients Wearing a Novel Device: Utilization During Cardiac Rehabilitation

Mobile Advanced Multi-Parameter Reporting in Patients Wearing a Novel Device: Utilization During Cardiac Rehabilitation

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05957172
Acronym
MAPS-III
Enrollment
0
Registered
2023-07-24
Start date
2023-01-31
Completion date
2023-10-31
Last updated
2023-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease, Cardiac Event, Cardiac Infarct, Heart Attack, NSTEMI, STEMI

Keywords

heart attack, myocardial infarction, STEMI, NSTEMI

Brief summary

Advanced remote multi-parameter reporting during cardiac rehabilitation (MAPS-III). The primary purpose of this observational study is to collect baseline information of cardiac rehabilitation usage in the US for post-myocardial infarction (MI) patients with EF \> 35% while wearing the ZOLL AMS device for 30 to 60 days. Secondary data on biometrics, arrhythmias, symptoms, and healthcare utilization will provide additional background information on this population during the early post-MI cardiac rehabilitation period.

Detailed description

To collect baseline data on cardiac rehabilitation usage (referrals and completion) in recent post-MI patients with EF \> 35%.To collect data on AMS-derived biometric data (e.g. HR, activity) and arrhythmias, and subject-reported symptoms, beta blocker/ivabradine usage (dose/changes) and cardiovascular events. The participating centers will enroll consenting subjects in a sequential manner to avoid preferential selection of patients to participate in the study. Subjects will be consented by the center study staff, and if eligible will wear the FDA-cleared AMS device for 30-60 days. Subject demographic information and clinical history will be obtained at the time of enrollment. During the study period, the prescribing physician-investigator will be blinded to AMS data. Final subject follow-up will be at 3 months. A sample size of 150 subjects is estimated in order to have 100 subjects with at least 30 days of AMS use for analysis.

Interventions

DEVICEZOLL Arrhythmia Management System

AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity, and body posture (biometric data)

Sponsors

Zoll Medical Corporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Both male and female subjects who are between 21 - 75 years of age, inclusively 2. Subjects who are consented and enrolled into the study prior to discharge from the qualifying acute myocardial infarction 3. Subjects with a consistent EF \>35% post the qualifying acute myocardial infarction

Exclusion criteria

1. Subjects with an implantable cardiac device such as left ventricular assistive device, pacemaker, an implanted cardioverter defibrillator (ICD), a cardiac resynchronization therapy device, subcutaneous ICDs, pressure monitors, and loop monitors. 2. Subjects with wearable cardioverter defibrillator, Holter monitors, wearable event recorders, and other mobile cardiac telemetry devices at the same time. 3. Subjects with a skin condition preventing them from wearing the AMS device. 4. Subjects who are non-ambulatory for any reason. 5. Subjects who are self-reporting to be pregnant. 6. Subjects with comorbidities that would preclude adherence to a cardiac rehabilitation program - at the discretion of the physician. 7. Subjects participating or planning to participate in another interventional study during the protocol-defined study period

Design outcomes

Primary

MeasureTime frameDescription
Cardiac rehabilitation program referrals and completions (in-clinic or home-based)30-60 daysMeasure the completion rate of patients undergoing cardiac rehabilitation programs i.e. the number of cardiac rehabilitation program referrals vs. number of cardiac rehabilitation program completions

Secondary

MeasureTime frameDescription
AMS-derived data - Activity30-60 daysChanges in total daily activity as detected by the AMS accelerometers
AMS-derived data - Arrhythmias30-60 daysOccurrence of Arrhythmias as detected by the AMS
AMS-derived data - Heart Rate30-60 daysImprovement in nighttime resting heart rate
Subject reported outcomes - Symptoms30-60 daysOccurrence and changes in symptoms recorded via weekly diary
Subject reported outcomes - Cardiovascular events30-60 daysCardiovascular events as measured by health care use i.e. unplanned health care provider visits due to cardiovascular event, recorded via weekly diary
Subject reported outcomes - Beta blocker/ivabradine usage/changes30-60 daysInitiation/Termination/Changes in beta blocker/ivabradine usage recorded via weekly diary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026